Our Pioneers Program brings together distinguished people from across healthcare, spanning pharma, academia, regulatory, and beyond, who have driven transformative change in their fields and in the lives of patients. ARTIS Pioneers transcend the role of a typical advisory board, playing active and impactful roles within the fund and our portfolio. In this edition of our Pioneer Spotlight, we sat down with Zain Kassam.

Zain Kassam's family didn't have a roadmap. His mother came to Canada as a refugee from East Africa, and his father's family had run a bakery in Kenya. As the son of immigrants, Zain grew up understanding there were really only three acceptable careers: doctor, lawyer, or engineer. He had little real exposure to any of them, and worked the counter at the family convenience store. Money was tight, but his parents understood that education was what would change his trajectory, and they sacrificed almost everything to put Zain and his brother through Montessori school and give him a better start. Alongside a fierce competitive streak and a handful of early talents, he developed an organic fascination with health and science, even racing middle school classmates to recite the taxonomic ranks.

That early fascination with biology, health, and the unsolved edges of medicine would run through his entire career. Over time it sharpened into a focus on the gut, shaped in part by watching his father live with ulcerative colitis. His research began with a high-school stint at the Ottawa Health Research Institute, surviving a near-detour into competitive debating, where he ranked among the best in North America, before a meeting with a judge on the Supreme Court of Canada nudged him toward science rather than law. From there, Zain studied health sciences at McMaster, the birthplace of evidence-based medicine; trained in medicine at Western University in London, Ontario; returned to McMaster for Internal Medicine and Gastroenterology; earned an MPH in quantitative methods at Harvard's T.H. Chan School of Public Health; and pursued a postdoctoral fellowship in microbiome engineering at MIT.

The combination is the point. Clinical GI, biostatistics, and engineering together helped Zain build a field rather than just practice in it. He was a co-founder and Chief Medical Officer of OpenBiome, the first public stool bank in the United States; co-founder and CMO of Finch Therapeutics, which he took through Phase II trials and a 2021 NASDAQ IPO; and is today CMO at Seed Health, an ARTIS portfolio company bringing evidence-based microbiome science directly to consumers. Behind the titles sit more than 200 peer-reviewed publications, 15 issued patents and patent applications, and a category of medicine that did not exist when he started.

Here, Zain shares why he chases unfashionable problems, why a fresh pair of eyes is a founder's superpower, why the most valuable thing you build is sometimes the infrastructure, and why the best ideas tend to come from connecting people and borrowing from one field to solve another. He also reflects on the hardest decisions he has faced, and what he would tell founders now.

When I was deciding what to focus on after my GI training, the original plan was to go deep, not wide. I was going to do IBD and the microbiome, which fit the thesis I had built in part around my dad’s experience with ulcerative colitis. The advice that changed everything was simple: that is a crowded area, so go to the room that's not full. Instead of going deep through the IBD lens, go wide and lateral across the microbiome, and the rooms will be open for you to operate in. I have carried that reframing through my entire career.

The pull toward contrarian bets was never about being contrarian for its own sake. It comes down to two things: impact and people. I only get truly excited when there is real impact at the patient and human level, and I believe you are the sum of the five people you work with. A bet that is genuinely high-impact, shared with the right team, is worth taking even when the rest of the room disagrees.

Going against the room also means getting laughed at, and I have learned to read the laughter. The first time I presented our early fecal-transplant data, I was still a trainee, standing next to a poster at DDW, the big GI meeting, with thirty thousand doctors in the building. Colleagues would wander past, glance at the work, and snicker. Poop, ha ha. I felt every bit of it. But I made a rule out of it: if I am getting laughed at, either I am genuinely off the path, or I am contrarian and right. If it is the second one, the impact is enormous, and that is energizing.

That is precisely what happened with OpenBiome; we helped expand access, support more than forty clinical trials, and move FMT into clinical guidelines. Through Finch, we helped build the technical foundation for FDA-approved microbiome therapeutics. The thing people had snickered at became a legitimate clinical category. No one was laughing anymore.

Years later it happened again, almost identically, when I presented probiotics data. Same laughter, same room. But there is real biology there. Many clinicians are not trained to think at the strain, species, or even organism-type level when they look at probiotics on a shelf. The term “probiotic” is a bit like the word “medicine.” Aspirin and Ozempic are both medicines, but you would never pool them together to judge efficacy. The field often does exactly that with probiotics. The science is real; the rigor often isn't, and that first-principles gap is exactly where you lean in.

The discipline is to be contrarian and principled. Don't take random bets. A lot of clinicians and entrepreneurs chase the ten percent better. You might be right, but are you going to dedicate your life to ten percent better? I want the stepwise changes, the things that totally transform. You might be wrong, and that is fine. In medicine, if you never take out a healthy appendix, it probably means you are missing some real appendicitis.

The best diagnoses, and the best companies, come from looking with fresh eyes. When I was a medical student on an infectious-disease team, I was sent to see a patient everyone had already written off as sinusitis. The patient had seen ten doctors. But the story didn't add up to me, and he had a strange lesion on his nose. I wanted to run the serology, and my senior resident gave me the classic line: when you hear hoofbeats, think horses, not zebras. We ran it anyway, just as a learning exercise. It came back as granulomatosis with polyangiitis, a rare vasculitis. The lesson stayed with me: sometimes the person with the fewest assumptions can ask the question everyone else has stopped asking. Questioning what the room takes for granted is how you disrupt, and how you ultimately deliver the greatest impact and the best standard of care.

That instinct is what launched everything. As a medical trainee, I treated an 82-year-old woman, devoted to her garden and grandkids, with severe, recurrent C. diff. She had taken antibiotics for a simple bladder infection and ended up with a devastating gut infection that nothing could touch, even the strongest drugs we had. By the time I saw her, in tears, she was asking whether removing her colon was the only option left. So we tried something that still carried real stigma: a fecal transplant, restoring her gut ecosystem with stool from a healthy donor, when almost no one was doing them. Two days later she was back gardening. It was the closest thing to a miracle I had seen, and the point at which the microbiome stopped being abstract science for me; it could change a life almost overnight. So I did the very McMaster thing and ran the meta-analysis. It worked more than ninety percent of the time, it was remarkably safe, and it had been in the Western literature since the 1950s, and in ancient Chinese medicine long before that. We had put a man on the moon and had supercomputers in our pockets, and no one had advanced this, largely because of the stigma around it. That was the moment I decided to lean all the way in.

I went to MIT to learn bioinformatics. Eric Alm convinced me, a medical doctor, to do a dry-lab postdoc in 2014, which was a genuinely strange thing for a clinician to do at the time. Boston changed how I thought about impact. Coming from a more traditional academic pathway, success was often measured by the academic impact of a paper. At MIT, I started thinking about success differently: impact on people, and the companies or systems you could build.

OpenBiome came from sitting next to a colleague, Mark Smith, who pointed out the absurdity of how we were doing fecal transplants. We were asking patients to recruit their own friends and family as donors, and clinicians were using coffee filters and blenders. We don't ask people to find their own blood donor; we have the Red Cross. So let's build the Brown Cross. It wasn't CRISPR or an algorithm. It was an operational innovation and centralization, which was exactly what made it powerful.

OpenBiome wasn't a therapeutic. It was the infrastructure that made an entire field possible. We scaled it like a rocket ship, reaching 200 employees within a couple of years and treating tens of thousands of patients. Before OpenBiome, roughly 11% of the U.S. population had access to this treatment. After, 99.7% were within a couple of hours' drive. As a small MIT spinout, we saved the healthcare system an estimated billion dollars. Sometimes the most valuable thing you can build isn't the product. It's the rails everyone else needs.

People often ask which structure they should build in, whether a nonprofit, a biotech, or a consumer company. My answer is always the same: it depends on the problem. It is about the right tool for the right problem, and different problems demand different vehicles. OpenBiome was a nonprofit, mission-funded and built for universal access. Finch was a venture-backed public biotech, built to take a microbiome therapeutic all the way through the FDA. Seed is a consumer microbiome-science company, built to reach millions of people now. I love all three, for very different reasons. The throughline is the microbiome, and the question is always the same: what is the problem I am actually solving, and which model fits it?

I also think the best innovations come from connecting things that don't usually sit together. Atul Gawande, a surgeon, cut surgical complications dramatically by borrowing the checklist from the airline industry, and he is a connector himself: surgeon, writer, speaker. That is the real skill. Not necessarily being the single best person at one narrow thing, but taking the best of one field and applying it to the next. For the first part of my career I went deep. Now I deliberately go wide, spending time with people entirely outside my world, because that is where the unexpected connections spark.

The hardest moments were never the science. Building these companies came with real challenges. At Finch, we were once fundraising on Christmas Day, with a plan already drafted to let go of most of the team. We pulled it off, but I felt every bit of it. Given my family background, the prospect of letting go of people I had hired, people with families and lives of their own, was the thing that kept me up at night.

We took Finch public in 2021. Not long after, just as the company was hitting its stride, my dad got very sick. Finch was my baby, but I had already lost my mom that year, and as a first-generation immigrant and the oldest son, there wasn't really a choice. I spent close to nine months back in Canada taking care of my dad: ten doctors, eight procedures, six new medicines. Thankfully, he is better now. I couldn't have done it any other way.

Holding those two tensions, founder and son, was terribly difficult, and I mourned stepping away. But it taught me the thing I hold dear today: people are whole humans, and they have human things going on. I have ultimate empathy for that now. Whether someone stays with the company or moves on, it is the human connection that lasts. I still mentor people across all of these companies who left them years ago.

If I distill what matters, it comes down to one word: TIME. Team, Impact, Memories, Energy. The team matters more than anything, because a good team can pivot and find the right problem. Memories matter more than we admit; the currency of a life well lived is a storyboard of memories, and you have to be intentional about curating them. And energy is about flow state, about how you feel working alongside exceptional people.

Having sat in the founder's seat a few times now, here is what I would pass along to any other founder.

Find the thing that genuinely obsesses you. Not something you just work hard at, but an idea that consumes you in such an energizing way that it becomes the fuel to run through a wall. Pair that obsession with deep curiosity and you have what carries a company through the hard parts.

Then get great at communication, because it is the most underrated founder skill. There is a YouTube series called Five Levels where an expert explains one concept to a child, then a teenager, then a college student, then a grad student, then another expert. That ability to move up and down the ladder is, to me, the single most important skill, because it is how you build teams, recruit, and persuade. The rare, advanced version is being able to diagnose where someone already sits on that spectrum and meet them exactly there, not talking down, not talking up.

My mentor Eric did something even subtler. He already saw the whole idea, but he didn't want to own it. He would lay the breadcrumbs so you would arrive at it yourself and own it. It was Socratic. I try to weave that into everything: with teammates, consumers, patients, and family. In pharma and biotech, it is easy to miss the human layer, explaining the science without fully empowering the person on the other side. If instead you walk someone through a journey of discovery and let them make the connection themselves, that is what sticks.

Be a connector of people and ideas. Good things happen when you are. Some of the work I am proudest of is simply introducing two people who would never have found each other, and watching them go on to build something real together.

And over-index on team, more than you think you should. These are people you should want to spend weeks with just hanging out, not only for their value-add but for the human part. Founding a company is like a marriage, and founder breakups happen far more than anyone would like, so have the hard conversations about roles and how the business scales up front. Build your external team early, too. As a CMO, I started blocking off a coffee, or a lemonade, with a different chief medical officer every couple of weeks, just for a different viewpoint. I still do it with anyone I find interesting, and I end every conversation the same way: who are two people you think I should meet? That is how the best, most serendipitous ideas find you. And read Noam Wasserman's The Founder's Dilemmas. I wish I had read it ten years before I started; it is lessons driven by data, not just one person's story.

For all the branching out, Zain keeps coming back to the gut.

I still love the gut. It is where we have the biggest impact, and as Hippocrates put it, all disease begins there. But the frontier is using the gut to reach the rest of the body. Women's health in particular is badly underinvested and finally having a moment, and there is real, non-obvious biology in the gut-vagina axis. There are gut microbes that recycle estrogen through the beta-glucuronidase pathway rather than letting the body simply excrete it. That is the kind of legitimately scientific, under-explored connection I think we will see much more of: using the richest biological organ we have to do far more than what most people think of as gut health.

Asked the question he loves, what is the kindest thing anyone has ever done for you, Zain doesn't reach for a mentor or a lucky break, though he has plenty of both. He points back to his parents, and the bet they made on his education when the family had little. What stays with him is the asymmetry of it: a small act on one side that compounds, over a lifetime, into everything that came after.

It is a pattern he has watched repeat at every turning point since. A judge who steered him toward science. A professor who told him not to go home to the job waiting in Canada, but to stay at MIT a little longer. Each was a single conversation that felt like almost nothing to the person offering it, and changed the entire course of his. Now he tries to be that person. That is the quiet logic of the Pioneer role itself: to be the person on the other side of the table when a founder is at an inflection point, because you so rarely know which conversation is the one that changes a life.

‍